In this episode of "The Top Line," we talk with Dr Reanne Moore, an associate professor of psychiatry at the University of California San Diego, about the state of digital phenotyping. We also cover the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines.  To learn more about the topics in this episode: Nominations for Fierce Biotech's 2023 Fierce 15 close Friday—three more days to submit The Future of Biotech ADC puts Zynlonta study on hold after 7...

For sponsors, value lies in equipping sites with the technology that makes securely capturing pre-screening, recruitment, and enrollment data easier.  In this interview, Alicia Asgari, the Senior Manager of Solutions Consulting at OneStudyTeam, discusses the need for appropriate technology solutions and strategies for sponsors and sites to solve recruitment and enrollment challenges. OneStudyTeam is a provider of cloud-based software and enrollment solutions for sponsors, sites, and CROs...

In this episode of "The Top Line," we talk with ViiV’s head of R&D, Dr. Kimberly Smith, about new HIV therapies. We also cover Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines.  To learn more about the topics in this episode: Explore the categories of the Fierce 50 AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors Boehringer Ingelheim launches first interchangeable biosimilar to AbbVie's...

In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about transgender care, light therapy, and the rest of the week's headlines.  To learn more about the topics in this episode: 'Podnosis': Medicaid eligibility determinations, healthcare for the LGBTQ+ community Introducing the Fierce 50: Honoring healthcare and biopharma champions fighting for...

In this episode of "The Top Line," we talk with Fierce’s Eric Sagonowsky and Kevin Dunleavy about the most expensive drugs in the U.S. We also cover Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines.  To learn more about the topics in this episode: 'Misinformation': AstraZeneca's China head refutes news report about potential spinoff Deadline extended: Biopharma's collective memory of COVID—in photographs Lilly...

In this episode of "The Top Line," we talk with Fierce’s Max Bayer and Angus Liu about the most important news coming from this year's annual BIO conference. We also cover a COVID lawsuit, an FDA-approved app, and the rest of the week's headlines.  To learn more about the topics in this episode: ASCO: After lung cancer fails, Roche's faith in TIGIT rewarded as tiragolumab shows signs of life in liver cancer Merck ends last Keytruda trial in aggressive prostate cancer campaign, takes...

In this episode of the "The Top Line," we talk with Fierce’s Gabrielle Masson and Andrea Park about the most important news coming from this year's annual ASCO meeting. We also cover contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines.  To learn more about the topics in this episode: ASCO: Novocure's tumor-treating electric fields nearly double survival for some lung cancer patients  ASCO: Astellas exec jokes that 3 pending drug approvals are...

Victoria Summers, principal at ZS Associates, discusses patient centricity.

In this episode of the "The Top Line," Fierce’s Anastassia Gliadkovskaya talks with Autumn Ehnow, vice president of Medicines360, a nonprofit pharma with a mission to produce and sell affordable medications. They talk about the need to democratize access to medications like emergency contraception, particularly for women. We also cover Elizabeth Holmes, the state of Alzheimer's research, plus more headlines.  To learn more about the topics in this episode:  Startup Curae Pharma360 partners...

In this episode of the "The Top Line," Fierce Pharma's Fraiser Kansteiner and Eric Sagonowsky discuss the 20 most influential people in biopharma. We also cover a new topical gene therapy from Krystal Biotech, the FDA approval of Brixadi to treat patients with opioid use disorder, plus more headlines.  To learn more about the topics in this episode:  The most influential people in biopharma in 2023 FDA clears Braeburn's long-acting Brixadi to treat opioid use disorder Krystal's Vyjuvek...

Layoffs have hit biopharma hard over the last year and a half. In this episode Fierce's Max Bayer and Gabrielle Mason will discuss the recent trends. We'll also cover a gene therapy by Sarepta Therapeutics, Abbott's FDA approval, plus this week's headlines.  To learn more about the topics in this episode:  Layoffs continue to batter biotech, with Big Pharmas piling on the pain Abbott's spinal cord stimulators score FDA approval to treat nonsurgical back pain Theranos' Elizabeth Holmes...

On March 29, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner concludes our miniseries to explore what that means for the opioid epidemic. We'll also cover a possible over-the-counter birth control, a COVID test recall, plus this week's headlines.  To learn more about the topics in this episode:  Lilly's hotly...

Dr. Christopher Piorkowski, Divisional Vice President and Chief Medical Officer of Abbott's Electrophysiology business, is the latest guest on The Top Line podcast.A seasoned expert in the field of electrophysiology, he joins us to discuss and explain some of Abbott’s latest solutions and advancements, as well as best practices to support treatment for abnormal heart rhythms. EnSite X, for example, is Abbott’s revolutionary 3D heart mapping software which Piorkowski describes as the...

On March 29th, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of The Top Line, Fierce Pharma staff writer Fraiser Kansteiner continues our mini-series to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives. To learn more about the topics in this episode:  Emergent makes...

On March 29th, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of The Top Line, Fierce Pharma staff writer Fraiser Kansteiner launches a mini-series to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives. To learn more about the topics in this episode:  Emergent makes...

2022 was the third straight year where the coronavirus pandemic had an extreme effect on the revenue of several biopharma companies. Pfizer became the first company in industry history to rack up more than 100 billion dollars in sales. We discuss how other companies fared in 2022 and what we can expect this year.  To learn more about the topics in this episode:  The top 20 pharma companies by 2022 revenue Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace...

Fierce Biotech regularly pulls together the industry’s top money raisers from the year before. Staff writer Gabrielle Masson and Editor-in-Chief Ayla Ellison discuss a few of the biotechs at the top of the list.  Plus, in this episode, we cover Johnson & Johnson's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines.  To learn more about the topics in this episode:  Biotech's top money raisers of 2022 Johnson & Johnson's $8.9B bankruptcy...

For a long time, AbbVie’s Humira was the world’s top-selling drug. But the bestseller will finally face biosimilar competition. Plus, this year is also chock-full of other big-name, blockbuster drugs headed for the patent cliff. In this episode, we discuss 2023's patent story.  Plus, we cover how Johnson & Johnson is looking to end its talc litigation with a sweeping settlement and more of this week's top headlines.  To learn more about the topics in this episode:  The top 10 drugs...

2022 was a tough year for biotechs in anyone’s book. At Fierce, we recorded 119 companies that resorted to laying off staff. And judging by the Fierce Biotech Layoff Tracker, 2023 is looking like more of the same. Fierce Biotech’s James Waldron sat down with Glenn Hunzinger, the U.S. pharma and life science leader at PwC, to talk about the financial trends he expects biotechs to face in 2023.  Plus, in this episode, we cover Emergent's Narcan over-the-counter approval, the first PTSD...

This year kicks off the second decade of Fierce Medtech’s annual Fierce 15 report. Not surprisingly, the startups featured on this year’s list are raising the bar for medtech developers everywhere. Staff writer Andrea Park and Editor-in-Chief Ayla Ellison discuss a few of the 15 startups that made the cut.  Plus, in this episode, we cover Illumina and Carl Icahn's proxy battle, Sanofi slashing insulin prices and more of this week's top headlines.  To learn more about the topics in this...

Is it all bad news in the bear market? Not necessarily. After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative performance for biotech stocks, with the SPDR S&P Biotech ETF XBI extending net losses over a 70-week period.  But things are looking up: the XBI was 7% up in January of this year, and investor...

The sudden failure of Silicon Valley Bank sent shock waves across global markets. Fierce Biotech Senior Editor Annalee Armstrong talked with Kiah Haslett, managing editor of the publication Bank Director, about how SVB’s failure came to be and what to expect next. Armstrong and Fierce staff writer Max Bayer chat about how the biotech sector reacted given that SVB served almost half of all venture-backed technology and life sciences companies. They reflect on what surprised them...

Some expect the next few years will be an overall down period for pharma growth. So, Fierce’s Kevin Dunleavy invited Harietta Eleftherochorinou, Ph.D., of IQVIA to "The Top Line" to discuss why pharma needs to employ artificial intelligence and machine learning tools to stay ahead of the curve. To learn more about the topics in this episode:  2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products Covis finally pulls preterm birth drug...

M&A plummeted in 2022 compared to the previous year. But some medtech companies were still able to pull off multibillion-dollar megadeals. We tracked it all on Fierce Medtech’s list of the 10 biggest M&A moves in 2022. In this episode, we discuss some high points from the roundup.  To learn more about topics in this episode: The top 10 medtech M&A deals of 2022 Acquisitive Pfizer to strike again? Seagen back in M&A talks after Merck walked away: WSJ Eli Lilly slashes...